PharmAthene Inc.: Government giving Emergent BioSolutions unfair advantage in anthrax contracting

Annapolis-based biodefense company PharmAthene Inc. filed a complaint against the Department of Health and Human Services, claiming it is giving a de facto sole-source anthrax contract to competitor Emergent BioSolutions Inc. with its latest solicitation. In a protest filed with the U.S. Government Accountability Office, officials from PharmAthene said the solicitation was written in a way that eliminated competition and ensured that an award for a next-generation anthrax vaccine would go to Gaithersburg-based…
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Condition:   Anthrax Interventions:   Biological: AV7909;   Biological: BioThrax Sponsors:   Emergent Product Development Gaithersburg, Inc.;   Biomedical Advanced Research and Development Authority Recruiting
Source: - Category: Research Source Type: clinical trials
During the Feb. 27-28 meeting of the CDC's Advisory Committee on Immunization Practices, the group voted to update recommendations for the Japanese encephalitis vaccine, along with guidance on pre-exposure prophylaxis anthrax vaccination.
Source: AAFP News - Category: Primary Care Source Type: news
(MedPage Today) -- Also, ACIP issues new language on vaccines for anthrax and Japanese encephalitis
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news
Publication date: Available online 26 January 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Emerson B. Lee, Hyeong-Min Jeon, Chang-Ung Kim, Sang M. Park, Geunyoung Cho, Hyun-Jin Kim, Youngjin Kim, Doo-Jin Kim, Young S. Kim, Hayyoung Lee, Jie-Oh LeeAbstractHemagglutinin (HA) displayed on a ferritin nano-cage has been shown to be effective in generating a potent immune response against a broad range of influenza infections. Here, we showed that conjugation of flagellin together with HA to the exterior surface of the ferritin cage greatly enhanced not only the humoral immune response in mice but als...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
AbstractBacillus anthracis (BA), the etiological agent of anthrax, secretes protective antigen (PA), lethal factor (LF), and edema factor (EF) as major virulence mediators. Amongst these, PA-based vaccines are most effective for providing immunity againstBA, but their low shelf life limits their usage. Previous studies showed that B-cell epitopes, ID II and ID III present in PA domain IV possess higher toxin neutralization activity and elicit higher antibody titer than ID I. Moreover, N-terminal region of both LF and EF harbors PA-binding sites which share 100% identity with each other. Here, in this study, we have develop...
Source: Medical Microbiology and Immunology - Category: Microbiology Source Type: research
Military analysts are increasingly concerned about the nation ’ s “ advanced, underestimated and highly lethal ” bioweapons program.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Defense and Military Forces Biological and Chemical Warfare North Korea United States International Relations Smallpox United States Politics and Government Microbiology Anthrax Vaccination and Immunization Nuclear Weapons Belfer Cente Source Type: news
CONCLUSIONS: ELP chimeric antigen could be considered as a high immunogenic antigen. PMID: 30621469 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
NIH findings with potential for enhancing human health include vaccines against HIV, anthrax, and plague, a wearable ultrasound patch to track blood pressure, and a technique to regrow neurons across scarred spinal tissue.
Source: NIH Research Matters from the National Institutes of Health (NIH) - Category: Consumer Health News Source Type: news
Scientists engineered a vaccine that protects animals from both anthrax and plague. After more development and testing, the approach could be used to combat public health threats.
Source: NIH Research Matters from the National Institutes of Health (NIH) - Category: Consumer Health News Source Type: news
This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier.
Source: NIDDK Research Resources - Category: Endocrinology Source Type: research
More News: Anthrax | Anthrax Vaccine | Biotechnology | Contracts | Department of Health | Government | Health | Health Management | Vaccines